The price of sofosbuvir purchasing daclatasvir in 2016 is 15010438677

Sofosbuvir
Hepatitis C is most likely to be missed and the infection will have serious consequences
Research shows that %-% of chronic hepatitis C patients develop cirrhosis and liver cancer years after infection, and the incidence of liver cancer surges to %-% . The incidence rate of hepatitis C in China is .%, which is equivalent to about 10,000 hepatitis C patients. Due to the insidious nature of the unpreventable onset of hepatitis C and the fact that hepatitis C is not tested in routine physical examinations, more than 90% of patients only seek medical treatment in the late stage of the disease, missing the best opportunity for treatment, allowing hepatitis C to cause cirrhosis of the liver. The mortality rate caused by failure and hepatocellular carcinoma has greatly increased
The main reason why hepatitis C patients easily slip through the net is that its onset is insidious and difficult to detect. At the same time, there is insufficient publicity about hepatitis C. Most people are not interested in checking for hepatitis B virus. The six items and transaminases are paid more attention to, but the screening of hepatitis C virus antibodies is not included in the routine examination. There are even fewer cases of checking hepatitis C virus ribonucleic acid, resulting in some patients slipping through the net. Secondly, because approximately 1/2 of hepatitis C patients have normal or basically normal aminotransferase levels and relatively insidious symptoms, another group of hepatitis C patients may be missed through screening only through aminotransferase levels.
In addition, the current common test method for hepatitis C serum markers is to detect hepatitis C antibodies (anti-). However, after infection with hepatitis C virus, the anti- The period during which antibodies can be detected in peripheral blood (months or even years) is also the main reason why hepatitis C is easily missed.
Different from hepatitis B, the liver lesions of simple hepatitis B virus carriers are mild and can be left untreated as long as regular follow-up and observation. However, hepatitis C, on the contrary, will continue to damage the liver once infected. Therefore, no matter whether the patient has symptoms or not, whether the transaminases are normal or not, as long as hepatitis C virus is carried in the body, it should be eliminated as soon as possible without delay. Jiang Fangqing said that China's "Guidelines for the Prevention and Treatment of Hepatitis C" clearly stated that drug combination therapy is currently the most effective antiviral treatment option. The cure rate of hepatitis C can reach %-% when treated with sufficient dosage for one year.